PeptideOS · therapeutic peptides, approved to gray market
What is the evidence that it works in people? Is it legal where you are?
An evidence and regulatory map with no dosing, no vendors and no advice. Every compound gets the same treatment: evidence tier first, regulatory status from primary sources, then what nobody knows. Mechanism comes last.
8 of 37compounds here have no published randomised human trial for any use. 22 have at least one claimed use with none.
E1·18
E2·16
E3·38
E4·14
E5·1
E6·19
E7·2
E8·5
Sorted by the best-supported use, strongest first. Tiers run from E1 multiple adequate RCTs to E8 no published efficacy evidence in any model; colour encodes knowledge, not danger (rubric). Each small bar marks one claimed use.
E1Multiple adequately powered RCTs, consistent
Afamelanotide
A · ApprovedMelanotan-1, MT-1, [Nle4, D-Phe7]-alpha-MSH
Phototoxicity in erythropoietic protoporphyria (adults) (E1); Nonsegmental vitiligo (with narrowband UV-B phototherapy) (E3); Cosmetic tanning in healthy people (gray-market 'Melanotan-1' claim) (E3)
Bremelanotide
A · ApprovedPT-141, Vyleesi
Hypoactive sexual desire disorder (HSDD) in premenopausal women (E1); Erectile dysfunction in men (gray-market claim; not an approved use) (E3)
Cagrilintide
B · Investig.CagriSema (fixed co-formulation with semaglutide)
Weight management in adults with overweight or obesity, with or without type 2 diabetes (cagrilintide plus semaglutide, CagriSema) (E1); Weight management in adults with overweight or obesity (cagrilintide alone) (E2)
Desmopressin
A · ApprovedDesmopressin acetate, DDAVP, 1-deamino-8-D-arginine vasopressin
Nocturia due to nocturnal polyuria in adults (E1); Primary nocturnal enuresis in children (E1); Central diabetes insipidus (E4); Haemophilia A and von Willebrand disease (bleeding prevention) (E4)
Icatibant
A · ApprovedIcatibant acetate, HOE 140, Firazyr
Acute attacks of hereditary angioedema (C1-inhibitor deficiency) (E1); ACE-inhibitor-induced angioedema (off-label) (E3)
Mazdutide
A · ApprovedXinermei
Weight reduction in obesity or overweight (E1); Type 2 diabetes: glycaemic control (E1)
Retatrutide
B · Investig.Weight reduction in obesity or overweight (the main use it is sold for) (E1); Type 2 diabetes: glycaemic control (E2); Knee osteoarthritis pain with obesity (E2); Obstructive sleep apnoea with obesity (E2); Liver fat (metabolic dysfunction-associated steatotic liver disease) (E3)
Semaglutide
A · ApprovedOzempic, Wegovy, Rybelsus
Type 2 diabetes: glycaemic control and cardiovascular outcomes (E1); Chronic weight management (obesity or overweight) (E1); Early Alzheimer's disease (oral semaglutide) (E1); Heart failure with preserved ejection fraction and obesity (E2); Metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis (E2); Knee osteoarthritis pain with obesity (E2); Alcohol use disorder (off-label, claimed) (E3)
Survodutide
B · Investig.Weight reduction in obesity or overweight (E1); Liver fat in obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) (E2); Metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis (E3)
Teriparatide
A · ApprovedPTH(1-34), rhPTH(1-34), Parathyroid hormone (1-34)
Postmenopausal osteoporosis (fracture prevention) (E1); Osteoporosis in men (E2); Glucocorticoid-induced osteoporosis (E2); Acceleration of fracture healing (off-label claim) (E3)
Tesamorelin
A · ApprovedTesamorelin acetate, TH9507, Egrifta
Excess abdominal (visceral) fat in adults with HIV-associated lipodystrophy (E1); Fatty liver (NAFLD) in people with HIV (E3); Visceral fat and cardiometabolic markers in people without HIV (abdominal obesity) (E3); Cognition in older adults and mild cognitive impairment (E3)
Tirzepatide
A · ApprovedMounjaro, Zepbound
Type 2 diabetes: glycaemic control and cardiovascular outcomes (E1); Chronic weight management (obesity or overweight) (E1); Obstructive sleep apnoea with obesity (E1); Heart failure with preserved ejection fraction and obesity (E2); Metabolic dysfunction-associated steatohepatitis (MASH) (E3)
E2At least one adequately powered RCT
Leuprorelin
A · ApprovedLeuprolide, Leuprolide acetate, Leuprorelin mesilate
Advanced prostate cancer (androgen deprivation) (E2); Endometriosis (pain) (E2); Uterine leiomyomata (fibroids), before surgery (E3); Central precocious puberty (E4)
Octreotide
A · ApprovedOctreotide acetate, SMS 201-995, Sandostatin
Acromegaly (biochemical control) (E2); Metastatic midgut neuroendocrine tumours (tumour growth control) (E2); Carcinoid syndrome (diarrhoea and flushing) (E3); Acute oesophageal variceal bleeding (off-label) (E3)
Setmelanotide
A · ApprovedImcivree
Acquired hypothalamic obesity (E2); Obesity in Bardet-Biedl syndrome (and Alström syndrome) (E3); Obesity due to POMC, PCSK1 or LEPR deficiency (E4)
E3Small, underpowered or conflicting RCTs
AOD-9604
C · Gray marketAOD9604, Tyr-hGH(177-191)
Weight loss and fat reduction in obesity (E3); Joint cartilage and osteoarthritis (E6)
BPC-157
C · Gray marketBPC 157, Body Protection Compound-157, Bepecin
Ulcerative colitis and inflammatory bowel disease (E3); Interstitial cystitis (bladder pain syndrome) (E4); Tendon, ligament, muscle and joint injury (E5); Stomach and gut lining injury (ulcers, NSAID damage, 'leaky gut') (E6)
CJC-1295
C · Gray marketCJC-1295 with DAC, CJC 1295
Raising GH and IGF-1 levels (pharmacodynamic marker, healthy adults) (E3); Growth in GHRH deficiency (E6); Muscle gain, fat loss, recovery, sleep and anti-ageing (gray-market claims) (E8); Visceral fat in people with HIV (E8)
Elamipretide
A · ApprovedSS-31, MTP-131, Bendavia
Barth syndrome (muscle strength, exercise capacity, fatigue) (E3); Primary mitochondrial myopathy (E3); Dry age-related macular degeneration with geographic atrophy (E3); Age-related decline in muscle function and exercise capacity (anti-ageing claims) (E3)
GHK-Cu
C · Gray marketCopper peptide GHK-Cu, Copper tripeptide, Glycyl-L-histidyl-L-lysine copper(II)
Diabetic foot ulcers (topical gel) (E3); Skin ageing, wrinkles and post-procedure skin (topical cosmetic) (E3); Injected GHK-Cu for tissue healing, inflammation or anti-ageing (E6)
GHRP-6
C · Gray marketGrowth hormone-releasing peptide-6, Growth hormone releasing hexapeptide
Growth hormone release (E3); Acute ischaemic stroke (with epidermal growth factor) (E3)
Hexarelin
C · Gray marketExamorelin
Growth hormone release (E3); Muscle mass and body composition (E4); Short stature in children (E4)
Ipamorelin
C · Gray marketIpamorelin acetate
Postoperative ileus (E3); Bone growth and bone mineral content (E6); Muscle gain, fat loss, recovery, sleep and anti-ageing (gray-market claims) (E8)
LL-37
C · Gray marketCathelicidin LL-37, Human cathelicidin antimicrobial peptide, Ropocamptide
Chronic venous leg ulcers unresponsive to standard care (topical synthetic LL-37) (E3); Diabetic foot ulcers (topical synthetic LL-37) (E3); Systemic or chronic infections and immune support (injected LL-37, gray-market claims) (E6)
Melanotan II
C · Gray marketMelanotan-II, MT-II, Melanotan 2
Erectile dysfunction and sexual desire in men (E3); Skin tanning (the main gray-market claim) (E4); Appetite suppression / weight loss (gray-market claim) (E6)
Selank
C · Gray marketSelank acetate, TP-7, Thr-Lys-Pro-Arg-Pro-Gly-Pro
Anxiety disorders (E3); Cognitive enhancement (memory, attention) (E6); Stroke (E6)
TB-500
C · Gray marketTB500, Thymosin beta-4 fragment (LKKTETQ), Ac-LKKTETQ
Chronic skin wounds and ulcers (full-length thymosin beta-4, not TB-500) (E3); Injury recovery: tendon, ligament, muscle and skin wounds (TB-500 fragment itself) (E6)
Thymalfasin
C · Gray marketThymosin alpha-1, Thymosin α1, Ta1
Chronic hepatitis B (E3); Chronic hepatitis C (E3); Sepsis (E3); Cancer (adjunct to chemotherapy; metastatic melanoma as the main tested setting) (E3); COVID-19 (E4); Chronic fatigue syndrome (ME/CFS) (E8)
E4Uncontrolled or non-randomised human trials
Follistatin-344
C · Gray marketFollistatin 344, FS344, FST344
Muscle disease via follistatin-344 gene therapy (a different intervention) (E4); Muscle growth and strength (injected follistatin-344 protein) (E8)
Kisspeptin-10
C · Gray marketKP-10, Metastin 45-54, Kisspeptin 112-121
Low testosterone / secondary hypogonadism in men (E4)
Semax
C · Gray marketACTH(4-7)PGP, ACTH(4-10) analogue Semax, Met-Glu-His-Phe-Pro-Gly-Pro
Recovery after ischaemic stroke (E4); Cognitive enhancement (memory, attention, focus) (E6); Anxiety (E6)
Sermorelin
C · Gray marketSermorelin acetate, GHRH(1-29)NH2, GRF(1-29)
Idiopathic growth hormone deficiency in children (former US-approved use) (E4); Age-related decline in growth hormone, body composition and strength in older adults (anti-ageing claims) (E4)
E6Animal models only
Dihexa
C · Gray marketDihexa acetate, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
Cognitive enhancement / dementia (E6)
Epitalon
C · Gray marketEpithalon, Epithalone, AEDG peptide
Anti-ageing / lifespan extension (E6); Telomere lengthening (E7)
KPV
C · Gray marketLys-Pro-Val, Lysine-proline-valine, alpha-MSH(11-13)
Inflammatory bowel disease and gut inflammation (E6); Wound healing (E6); Inflammatory skin conditions (psoriasis, eczema) (E7)
MOTS-c
C · Gray marketMitochondrial open reading frame of the 12S rRNA-c, Mitochondrial-derived peptide MOTS-c
Obesity, weight loss and insulin resistance (E6); Exercise performance, physical capacity and ageing (E6)
PE-22-28
C · Gray marketPE 22-28, Spadin analogue PE 22-28
Depression (E6)